Pharmascience Inc. introduces prpdp-LevETIRAcetam, an antiepileptic injection solution to its pediatric medicine line

To continue to increase the availability and effectiveness of drugs for its Canadian pediatric patients, PENDOPHARM, a division of Pharmascience Inc. is proud to announce the launch of a new formulation, a solution for injection of prpdp-LevETIRAcetam 100mg/mL.

prpdp-LevETIRAcetam will be the first intravenous solution of this antiepileptic agent with a new Health Canada approved indication for the pediatric population.

prpdp-LevETIRAcetam for Injection is indicated as adjunctive therapy in the treatment of:

  • Partial onset seizures with or without secondary generalization, in adolescents, children and infants, from one month of age, who have epilepsy;
  • Myoclonic seizures, in adolescents, from the age of 12 years, who have juvenile myoclonic epilepsy;
  • Primary generalized tonic-clonic seizures, in adolescents, from the age of 12 years, who have generalized idiopathic epilepsy.

“Canadians have been lacking a therapeutic option for the treatment of seizures with a favorable safety profile. Until today, Levetiracetam IV has not been available to Canadians while it has been available in Europe and the United States for over 10 years. Canada has fallen behind in its treatment options.” Jean-François Lemieux, Vice President and General Manager, PENDOPHARM, explains, “Canadians will be able to benefit from a new route of administration for the most prescribed antiepileptic drug in our country1prpdp-LevETIRAcetam solution for injection is the only treatment covering the broadest spectrum of seizures and offers a favourable safety and pharmacokinetic profile.”

“Pharmascience is proud to offer a new pediatric indication to treat serious diseases affecting children. Canada’s health care system has come a long way in terms of the availability of pediatric formulations. However, it continues to lag in comparison to other industrialized countries,” added David Goodman, President and CEO, Pharmascience Inc. “We must adapt our drug approval and reimbursement system, so more manufacturers are encouraged to introduce new pediatric formulations to help children and their caregivers. We must close this gap.”

The solution for injection of prpdp-LevETIRAcetam is the second product that PENDOPHARM is launching in this area, having introduced the oral solution prpdp-AMLODIPINE to its range of pediatric products earlier this year.

1. IMS data: CDH CompuScript :TRx MAT 2019 – Seizure disorder / Neurologist


Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 56th among Canada’s top 100 Research & Development (R&D) investors with over $43 million invested in 2018, Pharmascience Inc. is the 4th largest manufacturer of over-the-counter generic drugs in the country.

Pharmascience Inc. has strong values based on the importance of investing in its employees and young people. Through various programs and initiatives, the company ensures it supports their personal development and life. In 2019, Pharmascience Inc. has proudly been recognized for its investments by being selected as one of Canada’s Top Employers for Young People and named as one of Montreal’s best employers, as part of the Canada’s Top 100 Employers project. In 2018, the prestigious Forbes magazine ranked Pharmascience Inc. among its list of top 300 employers.

For important information, please refer to the Product Monograph at the following link: or also available by calling 1-888-550-6060.

For any questions about the solution for injection of prpdp-LevETIRAcetam 100mg/mL, please contact the PENDOPHARM Medical Information Department at 1-888-550-6060 or